Nephro Care India Approves Q3 Results, Announces Operational Changes and AGM Plans

Nephro Care India Approves Q3 Results, Announces Operational Changes and AGM Plans​

Nephro Care India Limited has approved its Standalone and Consolidated unaudited Financial Results for the quarter ended 30 June 2026. The results, which were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 7, 2026, show details across both segment and corporate levels.

The Board’s decisions extended beyond financial reporting, approving significant operational shifts and future governance structures for the company. Among the key outcomes were the approval of a Directors Report for the financial year ended March 31, 2026, and the sanctioning of the company's 12th Annual General Meeting (AGM) scheduled for September 25, 2026.

Operational Moves and Corporate Governance​

The Board meeting addressed several critical operational changes:

• Hospital Operations: The company approved the discontinuation of operations at Tulip Hospital, Ranchi.
• New Agreements: New partnerships were sanctioned, including approving the execution of the Hospital Operations & Management Agreement with PRAJATNA HEALTHCARE & DIAGNOSTIC LLP for the Malda Hospital. Additionally, the Board approved the Business Collaboration Agreement with Stone & Urology Clinic in Ranchi.
• AGM Planning: The company also approved the appointment of M/s Saptasikha & Co., Practicing Company Secretaries, as the Scrutinizer for the ensuing 12th Annual General Meeting.

Financial Performance Highlights (Quarter ended June 30, 2026)​

The results for the quarter ending 30 June 2026 were presented in both standalone and consolidated formats across various operational segments. The data provided below reflects key financial metrics:

Standalone Unaudited Financial Results (Q ended June 30, 2026)
(All amounts in ₹ lacs)


Consolidated Unaudited Financial Results (Q ended June 30, 2026)
(All amounts in ₹ lacs)

Fund Utilization Status​

The company also took note of a certificate from the Statutory Auditors regarding the utilization of funds raised through the IPO as of 30 June 2026. The utilized and unutilized amounts pertaining to the objects disclosed in the offer document are detailed below:


This information is part of the ongoing commitment by the company to ensure transparency and strengthen corporate governance for its shareholders.

NEPHROCARE Stock Price Movement​

Nephro Care India Limited shares rallied on Friday, closing at ₹75.80 after gaining 4.99%. The stock finished near its daily high and saw a volume of 25,200 traded during the session.